Kymera Therapeutics KYMR Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Kymera Therapeutics’s reported figures.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's free cash flow?
- Kymera Therapeutics (KYMR) reported free cash flow of -$89.27M in Q1 2026.
- How has Kymera Therapeutics's free cash flow changed year-over-year?
- Kymera Therapeutics's free cash flow decreased by 12.1% year-over-year, from -$79.62M to -$89.27M.
- What is the long-term trend for Kymera Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), Kymera Therapeutics's free cash flow has grown at a 15.8% compound annual growth rate (CAGR), from -$130.54M to -$234.34M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.